Why UHS is acquiring Talkspace

Featured Story

Why UHS Is Acquiring Talkspace for $835M

The news
Universal Health Services plans to acquire virtual behavioral health company Talkspace for $835 million. And it's a deal that makes a lot of sense for both parties, experts say.

The deal
Universal Health Services (UHS), based in King of Prussia, Pennsylvania, is a for-profit health system operating 29 inpatient acute care facilities, 346 inpatient behavioral health facilities and 168 outpatient and other facilities. New York City-based Talkspace has a network of about 6,000 professionals offering virtual therapy, psychiatry and medication management.

Joining forces will help "establish a truly national, end-to-end platform for behavioral health that seamlessly integrates virtual and in-person care," said Marc D. Miller, president and CEO of UHS. Talkspace will become a subsidiary of the UHS Behavioral Health Division, and UHS will bring on Talkspace's network of 6,000 therapists. This will expand the health system's reach to patients who prefer virtual care, especially younger populations, Miller said.

Talkspace will also be able to refer patients who are in need of more intensive outpatient, partial hospitalization or inpatient care to UHS' facilities.

An analyst's take
According to one healthcare expert, this is a strategic move for both companies. For UHS, the deal allows the company to recruit patients who primarily use telemedicine but may benefit from inpatient or outpatient services, as well as attract providers at a time when recruiting therapists is costly. For Talkspace, the acquisition gives them more stability.

"Think of Talkspace as a front door, as well as a mechanism to take advantage of its payer relationships across commercial and government payors. … For Talkspace, it provides stability in the face of volatile markets," said Christina Farr, managing director at consulting firm Manatt Health. "While this might not have been a deal that resembled the pandemic peak, it is still relatively healthy overall for a tech-enabled services company. The markets are aligning around the idea that telemedicine is here to stay, but it's a tool in the toolkit."

— By Marissa Plescia

How athenahealth is Solving Healthcare Interoperability & Powering Value-Based Care [Video]

Presented by athenahealth

Vice President, Product Management, Data and Ecosystem Platform, Sam Lambson talked about how its generative AI capabilities are helping clinicians. The more it lays pipes of connectivity for its EHR, the greater the context it can provide to support patient interaction. Watch now!

Nitra Rakes In $187M

The moolah
Nitra announced that it has raised $187 million in capital in the past six months. The startup, which launched in 2024, is based in New York, with offices in Washington, D.C. and Taipei.

The company has now raised a total of $205 million in capital and $90 million in equity. Some of its investors include Actions Capital, Comma Capital, Hyphen Capital, Mana Ventures, Necessary Ventures, New Enterprise Associates, Pantera Capital, Sazze Partners and Soma Capital.

The platform
Most healthcare practices still rely on a patchwork of disconnected systems to manage their payments, scheduling, supplies, insurance verification and inventory tracking, noted Jonathan Chen, co-founder and president of Nitra.

"That fragmentation creates a lot of manual work for clinics and takes time away from patient care. Our goal with Nitra is to bring those operational workflows into a single platform so practices can manage their back office more efficiently," he stated.

In his view, Nitra's platform combines most of the moving parts involved in running a healthcare practice. Instead of switching between multiple systems, clinics can manage payments, procurement, inventory, scheduling and insurance verification through one platform.

The value
More than 700 clinics currently use Nitra's platform. To Chen, the key value that Nitra provides is saved time for staff members. By allowing physicians and other employees to spend less time on back-office work, Nitra can free up people to focus more on patient care.

"Our view is that healthcare practices don't just need another tool. They need a platform that ties the operational side of their business together," Chen declared.

— By Katie Adams

Is This Vertex Pharma's Next Blockbuster Drug?

What's the news?
Vertex Pharmaceuticals immunology drug povetacicept, currently in clinical development for treating the rare kidney disorder immunoglobulin A nephropathy (IgAN), has preliminary Phase 3 data showing it reduced levels of a key protein by half. By the end of the month, the company expects an application seeking accelerated FDA approval will be complete, setting up the drug for a potential regulatory decision by late this year.

The drug
Povetacicept is a fusion protein engineered to block APRIL and BAFF, two signaling proteins that drive the IgAN's progression. The drug came from Vertex's $4.9 billion acquisition of Alpine Immune Sciences in 2024. Otsuka Pharmaceutical has an APRIL-blocking antibody drug approved in late 2025 for IgAN; a Vera Therapeutics fusion protein designed to block both APRIL and BAFF is under FDA review with a decision expected by mid-summer. Analysts say povetacicept's results suggest it could be best in class.

Why it matters
Vertex is trying to diversify its portfolio, which generates most of its revenue from cystic fibrosis drugs. The company has identified renal disease as one of its areas of focus, and povetacicept could play a big role. Analysts at William Blair project the drug could reach $2.1 billion in peak sales in the IgAN indication alone. But blocking APRIL and BAFF could also treat other autoimmune conditions, giving povetacicept pipeline-in-a-product potential.

Soundbite
"As a nephrologist, I am struck by the rapid, deep and sustained response to povetacicept, as well as the consistency of benefit across all subgroups," Vertex CEO Reshma Kewalramani said. "These results are important for patients with IgAN and also bring us one step closer to realizing povetacicept's pipeline-in-a-product promise."

—By Frank Vinluan

Chronic Overmedication: The Polypharmacy Waste and Safety Problem

Polypharmacy rarely starts with a mistake. It starts with care.
Nearly 42% of adults 65 and older are taking five or more prescription medications, and 12% are on ten or more at the same time, a pattern associated with a higher risk of drug interactions and adverse outcomes. For payers, that creates cost pressure on two fronts: higher pharmacy spend today and the risk of potential higher medical spend later should an adverse drug issues drive downstream care. When regimens include unnecessary or duplicative therapies, the waste adds up quickly, and so do the avoidable safety risks.

Full visibility is needed
Plans and payers are positioned to detect polypharmacy patterns early. Claims data can flag duplication, overlapping drug classes, high-risk combinations, and chronic oversupply long before the consequences show up. The problem is follow-through. If the only response is a retrospective review or a member-facing tool that requires extra work, change is less likely.

A better approach is to support prescribers and offer them full visibility into their patient's prescription list with patient-specific recommendations, such as therapeutic alternatives aligned to the plan's formulary, opportunities to discontinue duplicate therapy, or adjustments to quantity and days' supply, through the same channels clinicians already use. The most useful interventions come with a clear clinical rationale: the expected member and plan savings, and a prescriber-ready notification that can be acted on quickly. When the right information is easy to act on, unnecessary therapy is easier to identify and remove.

Helping to solve the problem
Fortunately, technology platforms can synthesize a patient's prescribing history and provide clinicians with the necessary data and analysis, enabling more accessible and effective decision-making around deprescribing. These platforms continuously scan pharmacy claims, plan rules, and formulary information to identify medication switching, deprescribing and deduplication opportunities, then deliver prescriber-ready recommendations inside existing workflows. Many also route accepted changes to the pharmacy and notify members, creating a closed loop that helps ensure the updated regimen is filled correctly and unnecessary refills stop.

Polypharmacy is a cost and safety problem that is solvable. The right technology platform can reduce it by identifying risky regimens, route specific "stop/switch/consolidate" opportunities to clinicians, and track whether changes stick through refill and adherence patterns.

— By MedCity Influencer Tom Dorsett

Video

Video: Inside NYU Langone's Health IT Innovation Space

Come on a short tour of NYU Langone's health IT innovation space in Midtown Manhattan.

In Other News

In the Absence of Objective Measures for ALS, Caregivers are the Only Witnesses. We Shouldn't Have To Be.

The way we measure ALS progression is failing patients. We are entering a new era of ALS therapeutics but still relying on the same blunt instruments of measurement.

Podcast

MedCity FemFwd: Inside Build Health International's New Maternal Center of Excellence in Sierra Leone

In this episode, we're joined by Allison Adamson, an architect at Build Health International. We discuss Build Health International's new Maternal Center of Excellence in Sierra Leone.

View Now

Breaking News

Why UHS is acquiring Talkspace